What Are GPCRs? The Receptor Family Most Research Peptides Bind

Research-use-only context. This article summarizes published third-party scientific literature and laboratory practice. It is not medical advice, not a therapeutic or performance claim, and not a usage guide. US Prime Peptides products are supplied strictly for in vitro laboratory research and are not for human or veterinary use.

Most of the peptides on a research catalog share one thing: the receptor they were discovered against is a G protein-coupled receptor, or GPCR. This article explains what a GPCR is, how its seven-helix architecture passes a signal across a membrane, what G proteins and arrestins do on the inside, and why short peptides are such natural ligands for this receptor family.

What a GPCR is

A G protein-coupled receptor is a membrane protein that crosses the lipid bilayer seven times and, when a ligand binds its outer face, changes shape so that a heterotrimeric G protein can bind its inner face and start a signal. GPCRs are the largest family of cell-surface receptors in the human genome. A 2003 Molecular Pharmacology analysis by Fredriksson and colleagues identified more than 800 human GPCR sequences and sorted them into five families by phylogeny: Glutamate, Rhodopsin, Adhesion, Frizzled/Taste2 and Secretin, the GRAFS system that most structural papers still use.

Two of those families matter for peptide research. The Rhodopsin family (class A) is the largest and includes the receptors for oxytocin, gonadotropin-releasing hormone, kisspeptin, ghrelin and the melanocortins. The Secretin family (class B1) is smaller, with 15 members, and includes the receptors for GLP-1, GIP, glucagon, growth hormone-releasing hormone, VIP and calcitonin-family peptides. The two families differ in how they hold a peptide, which is the subject of a later section.

In a 2017 Nature Reviews Drug Discovery survey, Hauser and colleagues counted roughly 475 approved drugs acting on 108 unique GPCR targets, about a third of all approved small-molecule and biologic drugs. That figure is about pharmacology in general, not about any research vial; it explains why so much receptor literature exists for peptide ligands.

The seven-transmembrane architecture

Every GPCR has the same basic plan: an extracellular N-terminus, seven alpha-helical transmembrane segments (TM1 to TM7) connected by three extracellular and three intracellular loops, and an intracellular C-terminus, usually with a short eighth helix lying along the inner face of the membrane. Pierce, Premont and Lefkowitz reviewed this layout in a 2002 Nature Reviews Molecular Cell Biology article that still serves as the standard introduction.

The ligand pocket sits inside the helical bundle, opened toward the extracellular side. The G protein binds a cavity that opens on the intracellular side when the receptor is active. The 2011 crystal structure of the beta-2 adrenergic receptor in complex with its G protein Gs, reported by Rasmussen and colleagues in Nature at 3.2 angstrom resolution and deposited as PDB entry 3SN6, showed the key movement: on activation, TM6 swings outward by about 14 angstroms at its cytoplasmic end, creating the pocket that the C-terminal alpha-5 helix of the G alpha subunit inserts into. Rosenbaum, Rasmussen and Kobilka summarized the structural basis of this family in a 2009 Nature review written just as the first non-rhodopsin structures became available.

A 2013 Nature paper by Venkatakrishnan and colleagues compared every GPCR structure then solved and found a conserved network of 24 inter-helix contacts, a structural scaffold shared across class A receptors even where sequence identity is low. The ligand-binding residues, by contrast, vary widely, which is why receptors that look nearly identical in the membrane can recognize ligands as different as a photon-activated retinal, a small amine and a 30-residue peptide.

How the signal gets across the membrane

An active GPCR works as a guanine nucleotide exchange factor: it catalyzes the release of GDP from the G alpha subunit, GTP binds in its place, and the G alpha-GTP and G beta-gamma units separate from the receptor to act on effector enzymes and channels. Weis and Kobilka laid out the molecular basis of this cycle in a 2018 Annual Review of Biochemistry article; Hilger, Masureel and Kobilka covered the structure and dynamics of the receptor-G protein complexes in a 2018 Nature Structural and Molecular Biology review.

Which G protein couples determines the second messenger. The table below lists the four main G alpha families and the effectors they regulate in cell systems.

These couplings are measured in transfected cell lines using cAMP accumulation assays, calcium-flux dyes or BRET biosensors. The numbers reported in the literature, potency (EC₅₀) and maximal response, describe a receptor in a defined cell system and nothing more.

Arrestins, desensitization and biased signaling

A GPCR does not signal through G proteins alone. Once active, it is phosphorylated on its C-terminus and intracellular loops by G protein-coupled receptor kinases (GRKs). The phosphorylated receptor recruits beta-arrestin, which sterically blocks further G protein coupling, links the receptor to clathrin-coated pits for internalization, and scaffolds its own signaling complexes such as ERK. Lefkowitz and Shenoy reviewed this second signaling arm in a 2005 Science paper.

Because a ligand can stabilize receptor conformations that favor one arm over the other, different ligands at the same receptor can produce different ratios of G protein to arrestin signaling. This is called biased agonism. Wootten, Christopoulos, Marti-Solano, Babu and Sexton reviewed its structural mechanisms in a 2018 Nature Reviews Molecular Cell Biology article, and Rankovic, Brust and Bohn discussed how it is measured and why it complicates the comparison of ligands in a 2016 Bioorganic and Medicinal Chemistry Letters review. For peptide research the practical point is that two ligands with the same binding affinity can produce different cellular responses, and a receptor-binding number alone does not predict a functional readout.

Why peptides are natural GPCR ligands

Peptides are natural GPCR ligands because the receptor family evolved alongside the body's peptide messengers. Hormones, neuropeptides and gut peptides are released, travel a short distance, bind a GPCR on a target cell and are then cleared by proteases. Muttenthaler, King, Adams and Alewood reviewed this ligand space in a 2021 Nature Reviews Drug Discovery article, noting that the majority of peptide ligands under study act at GPCRs. Read What Is a Peptide? for the chain-length chemistry behind this.

The two receptor families bind peptides differently. Class A peptide receptors hold the ligand inside the helical bundle, often with the peptide's C-terminus buried in the pocket and its N-terminus reaching toward the extracellular loops. Class B1 receptors carry a large extracellular domain of about 120 residues, and bind peptides by a two-domain mechanism: the extracellular domain grips the C-terminal helix of the peptide, which positions the peptide's N-terminus to insert into the helical bundle and trigger activation. Hollenstein and colleagues described this model and the first class B structures in a 2014 Trends in Pharmacological Sciences review. The 2017 cryo-EM structure of the activated GLP-1 receptor bound to GLP-1 and Gs, PDB 5VAI, shows the full arrangement in one complex. Our GLP-1 receptor primer covers that receptor in detail.

The two-domain mechanism explains a recurring pattern in the research literature: for class B1 ligands such as GLP-1, GHRH and VIP, truncating the N-terminus of the peptide by even two residues tends to produce a molecule that still binds the extracellular domain but no longer activates the receptor. That is why the N-terminal cleavage by dipeptidyl peptidase-4 matters so much for the GLP-1 family and why so much analog engineering is aimed at protecting that end of the chain.

GPCR targets across a research catalog

The table below maps common research peptides to the receptor each was characterized against in the published literature, with the receptor class and primary G protein. These are published receptor assignments from cell-based and structural studies. They describe what a receptor does in those systems, and say nothing about any outcome in an organism.

Two catalog names are missing from this table on purpose. BPC-157 and TB-500 have no confirmed GPCR, and the literature on them is mechanistic in other ways. Articles such as PT-141 and the melanocortin receptors go deeper on individual entries.

What receptor binding does and does not tell you

A receptor-binding figure describes a molecular interaction in a defined assay. It does not describe what happens in a tissue, an animal or a person, and it does not transfer from one cell system to another without being re-measured. Three limits apply to every number in the literature.

First, affinity and efficacy are different quantities. A ligand can bind tightly and activate weakly, or bind modestly and activate fully. Second, the readout depends on the expression level of the receptor and on which G protein and arrestin isoforms the host cell contains, which is why the same ligand can report different EC₅₀ values in HEK293 and CHO cells. Third, as the biased-agonism literature shows, a single assay captures one signaling arm. A GPCR paper that reports cAMP alone has not measured arrestin recruitment or internalization.

For a laboratory buying a research peptide, what the certificate documents is chemistry: identity by mass spectrometry, purity by HPLC, net peptide content and the contaminant panel. No standard certificate includes a receptor assay. The article on purity versus potency explains why those are separate measurements and what an activity assay would involve.

Frequently Asked Questions

What does GPCR stand for and what does it do?

GPCR stands for G protein-coupled receptor. It is a membrane protein with seven transmembrane helices that binds a ligand on the outside of a cell and, by changing shape, activates a heterotrimeric G protein on the inside, which then changes the level of a second messenger such as cAMP or calcium.

How many GPCRs are there in humans?

The 2003 phylogenetic analysis by Fredriksson and colleagues identified more than 800 GPCR genes in the human genome and grouped them into five families (Glutamate, Rhodopsin, Adhesion, Frizzled/Taste2 and Secretin). Roughly 400 of these are olfactory receptors; the remainder respond to hormones, neurotransmitters, peptides, lipids and light.

Which research peptides bind GPCRs?

Most of them. GLP-1 analogs, GIP analogs, GHRH analogs, ghrelin-receptor peptides such as ipamorelin, kisspeptin-10, gonadorelin, oxytocin, the melanocortin analogs and VIP all have a published GPCR target. BPC-157 and TB-500 are notable exceptions with no confirmed GPCR.

What is the difference between class A and class B GPCRs?

Class A (Rhodopsin family) receptors have a short N-terminus and bind ligands inside the seven-helix bundle. Class B1 (Secretin family) receptors have a large extracellular domain of about 120 residues that first captures the C-terminal part of a peptide hormone, then guides its N-terminus into the helical bundle to activate the receptor.

Citations

1. Fredriksson R, Lagerström MC, Lundin LG, Schiöth HB. The G-protein-coupled receptors in the human genome form five main families. Phylogenetic analysis, paralogon groups, and fingerprints. Mol Pharmacol. 2003;63:1256-1272. PMID 12761335
2. Pierce KL, Premont RT, Lefkowitz RJ. Seven-transmembrane receptors. Nat Rev Mol Cell Biol. 2002;3:639-650. PMID 12209124
3. Rosenbaum DM, Rasmussen SG, Kobilka BK. The structure and function of G-protein-coupled receptors. Nature. 2009;459:356-363. PMID 19458711
4. Rasmussen SG, DeVree BT, Zou Y, et al. Crystal structure of the β2 adrenergic receptor-Gs protein complex. Nature. 2011;477:549-555. PMID 21772288
5. Venkatakrishnan AJ, Deupi X, Lebon G, Tate CG, Schertler GF, Babu MM. Molecular signatures of G-protein-coupled receptors. Nature. 2013;494:185-194. PMID 23407534
6. Weis WI, Kobilka BK. The Molecular Basis of G Protein-Coupled Receptor Activation. Annu Rev Biochem. 2018;87:897-919. PMID 29925258
7. Hilger D, Masureel M, Kobilka BK. Structure and dynamics of GPCR signaling complexes. Nat Struct Mol Biol. 2018;25:4-12. PMID 29323277
8. Lefkowitz RJ, Shenoy SK. Transduction of receptor signals by beta-arrestins. Science. 2005;308:512-517. PMID 15845844
9. Wootten D, Christopoulos A, Marti-Solano M, Babu MM, Sexton PM. Mechanisms of signalling and biased agonism in G protein-coupled receptors. Nat Rev Mol Cell Biol. 2018;19:638-653. PMID 30104700
10. Rankovic Z, Brust TF, Bohn LM. Biased agonism: An emerging paradigm in GPCR drug discovery. Bioorg Med Chem Lett. 2016;26:241-250. PMID 26707396
11. Hollenstein K, de Graaf C, Bortolato A, Wang MW, Marshall FH, Stevens RC. Insights into the structure of class B GPCRs. Trends Pharmacol Sci. 2014;35:12-22. PMID 24359917
12. Hauser AS, Attwood MM, Rask-Andersen M, Schiöth HB, Gloriam DE. Trends in GPCR drug discovery: new agents, targets and indications. Nat Rev Drug Discov. 2017;16:829-842. PMID 29075003
13. Muttenthaler M, King GF, Adams DJ, Alewood PF. Trends in peptide drug discovery. Nat Rev Drug Discov. 2021;20:309-325. PMID 33536635
14. RCSB Protein Data Bank. 3SN6: Crystal structure of the beta2 adrenergic receptor-Gs protein complex. rcsb.org/structure/3SN6
15. RCSB Protein Data Bank. 5VAI: Cryo-EM structure of the activated Glucagon-like peptide-1 receptor in complex with G protein. rcsb.org/structure/5VAI

This article is for laboratory research reference only. US Prime Peptides products are supplied strictly for in vitro research. Not for human consumption.

Compliance Notice: US Prime Peptides products are supplied strictly for laboratory and academic research purposes only. They are not intended for human or veterinary consumption, diagnosis, treatment, or prevention of any disease. All content on this page is educational in nature and does not constitute medical advice or product claims. Researchers are responsible for handling these compounds in accordance with their institution’s safety protocols and applicable laws.